Description
Immune-mediated arthropathy (IMA) is a condition in which the immune system mistakenly attacks the tissues of the joints, leading to inflammation and pain. This condition often affects multiple joints simultaneously, known as polyarthropathy. There are two primary forms of IMA. The non-erosive form does not initially cause visible bone destruction, while the erosive form leads to the breakdown of joint surfaces and bones over time. Examples of non-erosive IMA include idiopathic polyarthropathy, drug-induced polyarthropathy, and polyarthropathy associated with chronic diseases. Erosive forms include rheumatoid arthritis and chronic polyarthropathy in cats. While IMA can affect both dogs and cats, it is more commonly seen in dogs.
Causes
The exact cause of immune-mediated arthropathy is often unknown (idiopathic). In some cases, the immune response is triggered by an underlying infection or disease, such as bacterial infections (e.g., Lyme disease) or viral infections. Drug-induced polyarthropathy can occur due to certain medications like sulfonamides. Additionally, polyarthropathy may develop secondary to chronic diseases, such as bacterial endocarditis, discospondylitis, or certain cancers.
Clinical Signs
Common signs of IMA include lameness, joint stiffness, pain, fever, and swelling in one or more joints. These symptoms can be intermittent or constant and may shift from one leg to another. The most frequently affected joints are the carpus (wrist), hock (ankle), and feet. In more severe cases, especially with systemic conditions like systemic lupus erythematosus (SLE), other organs may also be involved, leading to additional symptoms such as kidney or skin issues.
Breeds Most Impacted
Certain breeds are more predisposed to developing immune-mediated arthropathy. Breeds most commonly affected include:
• Greyhounds: Particularly prone to erosive polyarthropathy, often occurring in younger dogs under 3 years of age.
• Shetland Sheepdogs: This breed has a higher incidence of immune-mediated diseases, including polyarthropathy.
• Poodles: Standard Poodles, in particular, are more susceptible to immune-mediated conditions, including IMA.
• Shar-Peis: Known for various autoimmune disorders, Shar-Peis can be more prone to developing immune-mediated joint issues.
• Labrador Retrievers: Often affected by idiopathic polyarthropathy.
• Doberman Pinschers: This breed may be more susceptible to various autoimmune conditions, including immune-mediated arthropathy.
Feline polyarthropathy may affect cats between 1-5 years of age, but it is less breed-specific compared to dogs.
Diagnostic Tests
Diagnosis of immune-mediated arthropathy typically requires a thorough physical examination, along with x-rays and joint fluid analysis. X-rays are particularly useful in detecting erosive forms of the disease where joint damage is visible. Additional laboratory tests may be necessary to identify specific causes, such as SLE or rheumatoid arthritis. In chronic cases, further organ testing may be indicated to assess the extent of the disease.
Treatment Options
Treatment for IMA usually involves managing the immune response and inflammation. Glucocorticoids (steroids) like prednisone are commonly used to control symptoms, with the dosage gradually reduced as the condition improves. In mild cases, nonsteroidal anti-inflammatory drugs (NSAIDs) may be sufficient for long-term management. However, steroids and NSAIDs should not be used together due to the risk of severe gastrointestinal irritation and ulcers.
For cases that do not respond well to steroids alone, more potent immunosuppressive drugs, such as azathioprine, cyclophosphamide, or methotrexate, may be necessary. In severe erosive cases, surgical options like joint fusion (arthrodesis) may be considered. If a drug-induced polyarthropathy is suspected, discontinuing the triggering medication is crucial.
Follow-up Care
Immune-mediated arthropathy is often a chronic condition requiring long-term management and regular veterinary follow-up. Signs of severe erosive arthritis may take several months to resolve. Regular physical examinations and joint fluid analyses are essential to monitor the progression of the disease and the effectiveness of treatment. Periodic laboratory tests may also be needed to check for side effects of immunosuppressive therapy, such as bone marrow suppression or liver issues. In cats, annual testing for feline leukemia virus is recommended due to the increased risk of infection while on immune-suppressive medications.
Prognosis
The prognosis for IMA varies depending on the severity and form of the disease. In cases of mild, non-erosive arthritis without joint destruction, the prognosis is generally good, particularly if there is a positive response to initial steroid therapy. However, periodic flare-ups can occur, necessitating ongoing treatment. The prognosis is more guarded for cases involving severe erosive polyarthropathy, especially when multiple joints are affected, or in specific breeds like greyhounds, where the disease may be more aggressive.
Comments